Muscle Flashcards
General Muscle info
Myofibril = fusion of myoblast = multinuc muscle cell/fiber
Cell attach/Stab = Dystrophin (sim to spectrin)
Skl M = striated connected by CT in ECM. Dystrophin links actin cytoskeleton to integral glycoprotein complex that interacts with ECM (laminin/collagen) - transduces contractile force form intracell sarcomeres to ECM
Dystrophin interaction
Binds actin, dystroglycans, synaptophines, dystrobrevin. Attaches actin-cyto to PM and ECM linking actin cyto to laminin-2
Dystroglycan complexes
Alpha dystroglycan - binds ECM glycoprotein (laminin) and proteoglycan (agrin)
Beta dystroglycan - binds dystrophin, other adapter proteins and intracell signal proteins (GRB2)
Dystroglycan complex function
Confers structural stability during contraction. Absence = muscle fibers succesptible to dmg, loss DAP at sarcolemma and fragile sarcolemma leads to muscle degeneration
M repair and growth
Satellite cells and side pop cells
Sat cells lie in Basal Lamina of mature myotubes. Stress - act myoblasts - surface of myotubes - fuse with myofibers - mature cells
Stem cells = Side pop, in bone marrow/skel M wall. Diff into haematopocite and Sat cell
Satellite Cells
Form regenerated M fibers after M dmg. In D repair response cannot keep up with repeated dmg leading to CT and fat accumulation
Sat cells: shortened telomers limits reproductive capacity
Absence of dystophin and muscle destruction
Membrane destabalization: loss of DAP at sarcolemma - absence of phys link leading to fragile sarcolemma
Influx Ca leads to apoptosis and necrosis
Increased contraction induced injury leads to repeated degeneration and inflammation and eventual M destruction
Muscular dystrophies
Genetic, Dys= weakening, degen or abnorm development, severe presents at childhood. Progressive muscle weak and atrophy increases serum creatine kinase. Diagnosis via blood test, PCR, M biopsy. Supportive treatment
Dystrophin information
DMD: total loss
BMD: partial function
Largest gene, 7 promoters, 29 exons, repeat seq on introns = increased mutation
Cyto to sarcolemma-dystroglycan complex in M cells
What are the X-linked MD’s
DMD, Becker MD (BMD), Em Dr MD
DMD info
common and sever affecting cardiac and skl muscle (1/3.5k). 2/3 mutations from mother, 1/3 new, 10-20% mosaic
Xp21, 472kDa dys mutation - partial deletion, frameshift mutation, pt mutation - nonfunctional protein — No detectable Dystrophin in M
Clinical DMD
Norm birth, weak at 3-5yrs, leg weak = Gower’s sign, waddle, lordosis and scoliosis
Atrophy - wheelchair at 10-12 yrs, M contractions, cog impairment (down 20% IQ), resp and cardiac muscle increasingly impaired. Rarely live past 20-30 yrs due to resp or cardiac fail
DMD diagnosis
Increased serum creatine lvls, M biopsy = immunohistochem and western blot, PCR deletion screen
DMD carriers
No clin manifestation, 8% FM heterozygous have M weakness due to reduced X-inactivation
BMD
6/100k, Mut dystrophin: inframe insert/ deletion - partial function - more mild.
Onset late childhood, slow progression, variance
Em Dr MD
1/100k, AD form rare, mut in Emerin or Lam A/C
Defect in Lamin (IF) assembly/attach to nuc envelope - affects stressed tissue
Onset Childhood, affects skl and cardiac M
Joint deform and decreased mobility, cardiomyopathy, conductive defects, arrythmias in adult - pacemaker by 30 - sudden cardiac fail common
What are the autosomal MD
Myotonic Dystrophy, Facioscapulohumeral MD, Limb Girdle MD, Congenital MD
Myotonic Dystrophy
AD, 1/8k, myotonin protein kinase disorder, tri-nuc repeat disorder (CTG)= anticipation. Multisystemic.
Onset 20-40, slow M degen and myotonia (invol contractions), weak hands legs (gait) sternomastoids, Atrophy facial M - ptosis, haggered appearance
Facioscapulohumeral MD
Rare, AD, prog weak face, scap, up arms. Del of subtelometric tandem repeat (4q35 or t4q:10q)
Onset 10-40, inability to puff checks, facial weak ptosis, difficulty raising arms and winged scapula, progressive weak legs, sensorinereal hearing loss, arrythmias
Normal life expectency
Limb Girdle MD types
- LGMD1: AD, rare, adult onset, laminopathies, caveolin-3 mut (PM invag so sarcolemma membrane alteration)
- LGMD2: AR, 10-20 yrs, Calpain (alpha, beta, gamma, epsilon sarcoglycans), titin (assoc with myosin), telethonin mutations
Describe Sarcoglycenopathies (LGMD)
complex= N-glycosylated transmembrane protein (glycocalyx) linked to dystrophin via association with dystroglycan complex. Defect in assembly of sarcoglycans leads to:
- Disrupted interactions with dystroglycan protein complex
- Disrupted association of sarcolemma with ECM
LGMD clin
similar to DMD, weak prox M, 10-20, disabled at 20-25, Differences = Psedohypertrophy and contractions rare, no cog impair
Congenital MD
Onset birth, mut in laminin, gen M weak, resp insuff, contractures, seize, mental retard
Impaired myogenesis, synaptogenesis, and mechanical stability
Clinically variable
DMD treatment
- Myoblast transfer- Challeneges are Dys too large for viral vector, many cells need gene, immune rejects vector.
In trial: Stem cell therapy with systemic delivery
Upreg of utrophin (fetal homologue)